Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Bausch Health Provides Update For DUOBRII Filing | ||||||||||||
By: PR Newswire Association LLC. - 15 Feb 2019 | Back to overview list |
|||||||||||
LAVAL, Quebec, Feb. 15, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, announced that the U.S. Food and Drug Administration (FDA) will be unable to meet today's Prescription Drug User Fee Act (PDUFA) date for the New Drug Application for DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, for the topical treatment of plaque psoriasis in adults. The FDA is close to finalizing its review, and we expect a decision from the FDA shortly. About Bausch Health Caution Regarding Forward-Looking Information and "Safe Harbor" Statement
View original content to download multimedia:http://www.prnewswire.com/news-releases/bausch-health-provides-update-for-duobrii-filing-300796814.html SOURCE Bausch Health Companies Inc. |
||||||||||||
|
||||||||||||
Copyright 2019 PR Newswire Association LLC. | Back to overview list |